［1］CROSBIE EJ,KITSON SJ,MCALPINE JN,et al.Endometrial cancer［J］.Lancet,2022,399(10333):1412-1428.
［2］ARORA V,QUINN MA.Endometrial cancer［J］.Best Pract Res Clin Obstet Gynaecol,2012,26(3):311-324.
［3］RODOLAKIS A,SCAMBIA G,PLANCHAMP F,et al.ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma［J］.Hum Reprod Open,2023,2023(1):c57.
［4］National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines):Uterine neoplasms(Version 1.2024)［EB/OL］.［2023-09-20］.https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
［5］周蓉,王益勤,鹿群,等.早期子宫内膜癌保留生育功能治疗专家共识（2022年版）［J］.中国妇产科临床杂志,2023,24(2):215-219.
ZHOU R,WANG YQ,LU Q,et al.Expert consensus on fertility preservation therapy for early endometrial cancer(2022 edition)［J］.Chin J Clin Obstet Gynecol,2023,24(2):215-219.
［6］HWANG JY,KIM DH,BAE HS,et al.Combined Oral medroxyprogesterone/levonorgestrel-intrauterine system treatment for women with grade 2 stage IA endometrial cancer［J］.Int J Gynecol Cancer,2017,27(4):738-742.
［7］YU M,WANG Y,YUAN Z,et al.Fertility-sparing treatment in young patients with grade 2 presumed stage IA endometrioid endometrial adenocarcinoma［J］.Front Oncol,2020,10:1437.
［8］KANDOTH C,SCHUL TZ,CHEMIACK AD,et al.The cancer genome atlas research network.Integrated genomic characterization of endometrial carcinoma［J］.Nature,2013,497(7447):67-73.
［9］TANOS P,DIMITRIOU S,GULLO G,et al.Biomolecular and genetic prognostic factors that can facilitate fertility-sparing treatment(FST) decision making in early stage endometrial cancer(ES-EC):A systematic review［J］.Int J Mol Sci,2022,23(5):2653.
［10］GARZON S,UCCELLA S,ZORZATO PC,et al.Fertility-sparing management for endometrial cancer:Review of the literature［J］.Minerva Med,2021,112(1):55-69.
［11］PIATEK S,MICHALSKI W,SOBICZEWSKI P,et al.The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia:Case series of 30 patients and systematic review［J］.Eur J Obstet Gynecol Reprod Biol,2021,263:139-147.
［12］WEI J,ZHANG W,FENG L,et al.Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia:A meta-analysis and systematic review［J］.Medicine(Baltimore),2017,96(37):e8034.
［13］WANG Y,ZHOU R,WANG H,et al.Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia［J］.Int J Gynecol Cancer,2019,29(4):699-704.
［14］SHIM S,CHAE SH,SO KA,et al.Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer［J］.Gynecologic Oncology,2021,161(3):810-816.
［15］GUTTINGER A,CRITCHLEY HOD.Endometrial effects of intrauterine levonorgestrel［J］.Contraception,2007,75(6,Supplement):S93-S98.
［16］LEONE RMU,MARTINELLI F,DONDI G,et al.Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer:A retrospective study［J］.J Gynecol Oncol,2019,30(4):e57.
［17］FANG F,XU H,WU L,et al.LNG-IUS combined with progesterone ameliorates endometrial thickness and pregnancy outcomes of patients with early-stage endometrial cancer or atypical hyperplasia［J］.Am J Transl Res,2021,13(5):5412-5419.
［18］FALCONE F,LAURELLI G,LOSITO S,et al.Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer［J］.J Gynecol Oncol,2017,28(1):e2.
［19］FAN Z,LI H,HU R,et al.Fertility-preserving treatment in young women with grade 1 presumed stage ia endometrial adenocarcinoma:A Meta-analysis［J］.Int J Gynecol Cancer,2018,28(2):385-393.
［20］MINIG L,FRANCHI D,BOVERI S,et al.Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women［J］.Ann Oncol,2011,22(3):643-649.
［21］PASHOV AI,TSKHAY VB,IONOUCHENE SV.The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer:A pilot study［J］.Gynecol Endocrinol,2012,28(7):559-561.
［22］ZHANG Z,HUANG H,FENG F,et al.A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer［J］.Journal of Gynecologic Oncology,2019,30(4):e61.
［23］LYU Z,GUO Y.Metformin and its benefits for various diseases［J］.Front Endocrinol(Lausanne),2020,11:191.
［24］MITSUHASHI A,HABU Y,KOBAYASHI T,et al.Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients［J］.J Gynecol Oncol,2019,30(6):e90.
［25］PRODROMIDOU A,LEKKA S,FOTIOU A,et al.The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer:A systematic review and meta-analysis of randomized controlled trials［J］.J Gynecol Obstet Hum Reprod,2021,50(9):102164.
［26］MATSUO K,MANDELBAUM RS,CICCONE M,et al.Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia［J］.Int J Gynecol Cancer,2020,30(9):1331-1339.
［27］WANG Y,ZHOU R,ZHANG X,et al.Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia:A retrospective cohort study［J］.BMC Womens Health,2021,21(1):252.
［28］CHUNG YS,WOO HY,LEE JY,et al.Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer［J］.Am J Obstet Gynecol,2021,224(4):370-371.
［29］ZHANG X,ZHAO X,WANG C,et al.Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia［J］.Oncol Lett,2023,25(2):52.
［30］AKESSON E,GALLOS ID,GANESAN R,et al.Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS(Mirena?) treatment of endometrial hyperplasia:An immunohistochemical study［J］.Acta Obstetricia et Gynecologica Scandinavica,2010,89(3):393-398.
［31］FAWZY M,MOSBAH A,ZALATA K,et al.Predictors of progestin therapy response in endometrial hyperplasia:An immunohistochemical study［J］.The Egyptian Journal of Fertility of Sterility,2016,20(2):6-11.
［32］WESTIN SN,FELLMAN B,SUN CC,et al.Prospective phase Ⅱ trial of levonorgestrel intrauterine device:Nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer［J］.Am J Obstet Gynecol,2021,224(2):191.
［33］UPSON K,ALLISON KH,REED SD,et al.Biomarkers of progestin therapy resistance and endometrial hyperplasia progression［J］.Am J Obstet Gynecol,2012,207(1):31-36.
［34］RAFFONE A,TRAVAGLINO A,ZULLO FM,et al.Predictive accuracy of progesterone receptor B in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD insertion［J］.J Minim Invasive Gynecol,2021,28(6):1244-1253.
［35］VEREIDE AB,KAINO T,SAGER G,et al.Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors(PRA and PRB),and estrogen receptors(ER-alpha and ER-beta) in human endometrial hyperplasia［J］.Gynecol Oncol,2006,101(2):214-223.
［36］HUTT S,TAILOR A,ELLIS P,et al.The role of biomarkers in endometrial cancer and hyperplasia:A literature review［J］.Acta Oncol,2019,58(3):342-352.
［37］TRAVAGLINO A,RAFFONE A,SACCONE G,et al.PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer.A systematic review and meta-analysis［J］.Eur J Obstet Gynecol Reprod Biol,2018,231:104-110.
［38］MINAGUCHI T,NAKAGAWA S,TAKAZAWA Y,et al.Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ⅰa,G1 adenocarcinoma of the endometrium［J］.Cancer Lett,2007,248(1):112-122.
［39］CHEN H,LUCAS E,STRICKLAND AL,et al.Specific biomarker expression patterns in the diagnosis of residual and recurrent endometrial precancers after progestin treatment:A longitudinal study［J］.Am J Surg Pathol,2020,44(10):1429-1439.
［40］LI C,BAI Y,YAN L,et al.SPAG9 may be a potential prognostic marker of endometrial hyperplasia and grade 1 endometrioid adenocarcinoma treated with progestin［J］.Gynecol Obstet Invest,2016,81(3):267-274.
［41］ZHANG H,YAN L,BAI Y,et al.Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia［J］.Gynecol Oncol,2015,136(3):549-553.
［42］TRAVAGLINO A,RAFFONE A,GENCARELLI A,et al.Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment［J］.International Journal of Gynecology & Obstetrics,2022,158(3):742-747.
［43］JEONG O,BROADDUS RR,LESSEY BA,et al.MIG-6 is critical for progesterone responsiveness in human complex atypical hyperplasia and early-stage endometrial cancer［J］.International Journal of Molecular Sciences,2022,23(23):14596.